{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:47:44Z","timestamp":1795027664983,"version":"4.10.2"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"publisher","award":["IRGC-04-SI-17-142"],"award-info":[{"award-number":["IRGC-04-SI-17-142"]}],"id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The mechanism of tumor immune escape and progression in colorectal cancer (CRC) is widely investigated <jats:italic>in-vitro<\/jats:italic> to help understand and identify agents that might play a crucial role in response to treatment and improve the overall survival of CRC patients. Several mechanisms of immune escape and tumor progression, including expression of stemness markers, inactivation of immunoregulatory genes by methylation, and epigenetic silencing, have been reported in CRC, indicating the potential of demethylating agents as anti-cancer drugs. Of these, a chemotherapeutic demethylating agent, Decitabine (DAC), has been reported to induce a dual effect on both DNA demethylation and histone changes leading to an increased expression of target biomarkers, thus making it an attractive anti-tumorigenic drug.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We compared the effect of DAC in primary 1076 Col and metastatic 1872 Col cell lines isolated and generated from patients\u2019 tumor tissues. Both cell lines were treated with DAC, and the expression of the NY-ESO-1 cancer-testis antigen, the PD-L1 immunoinhibitory marker, and the CD44, Nanog, KLF-4, CD133, MSI-1 stemness markers were analyzed using different molecular and immunological assays.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>DAC treatment significantly upregulated stemness markers in both primary 1076 Col and meta-static 1872 Col cell lines, although a lower effect occurred on the latter: CD44 (7.85 fold; ***p\u2009=\u20090.0001 vs. (4.19 fold; *p\u2009=\u20090.0120), Nanog (4.1 fold; ***p\u2009&lt;\u20090.0001 vs.1.69 fold; ***p\u2009=\u20090.0008), KLF-4 (4.33 fold; ***p\u2009&lt;\u20090.0001 vs.2.48 fold; ***p\u2009=\u20090.0005), CD133 (16.77 fold; ***p\u2009=\u20090.0003 vs.6.36 fold; *p\u2009=\u20090.0166), and MSI-1 (2.33 fold; ***p\u2009=\u20090.0003 vs.2.3 fold; ***p\u2009=\u20090.0004), respectively. Interestingly, in the metastatic 1872 Col cells treated with DAC, the expression of both PD-L1 and NY-ESO-1 was increased tenfold (*p\u2009=\u20090.0128) and fivefold (***p\u2009&lt;\u20090.0001), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We conclude that the upregulation of both stemness and immune checkpoint markers by DAC treatment on CRC cells might represent a mechanism of immune evasion. In addition, induction of NY-ESO-1 may represent an immuno-therapeutic option in metastatic CRC patients. Finally, the combination of DAC and anti-PD-1\/anti-PD-L1 antibodies treatment should represent a potential therapeutic intervention for this group of patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-023-04073-y","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T16:02:56Z","timestamp":1680278576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy"],"prefix":"10.1186","volume":"21","author":[{"given":"Nassiba","family":"Taib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maysaloun","family":"Merhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varghese","family":"Inchakalody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarra","family":"Mestiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereena","family":"Hydrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karama","family":"Makni-Maalej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsheen","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fairooz","family":"Sahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parveen B.","family":"Nizamuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Queenie","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeenath Safira K. M.","family":"Yoosuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salam","family":"Almoghrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lobna","family":"Al-Zaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaaeldin","family":"Shablak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Maccalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Ussama","family":"Al Homsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5526-7496","authenticated-orcid":false,"given":"Said","family":"Dermime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"issue":"6","key":"4073_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"4073_CR2","unstructured":"American Cancer Society. Colorectal Cancer Facts and Figures 2020\u20132022. Atlanta: American Cancer Society; 2020. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/colorectal-cancer-facts-and-figures\/colorectal-cancer-facts-and-figures-2020-2022.pdf."},{"issue":"1","key":"4073_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"Y-H Xie","year":"2020","unstructured":"Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1):1\u201330.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"4073_CR4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","volume":"170","author":"T Yu","year":"2017","unstructured":"Yu T, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548-563.e16.","journal-title":"Cell"},{"key":"4073_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.995882","volume":"9","author":"L Chen","year":"2022","unstructured":"Chen L, et al. Mechanisms on chemotherapy resistance of colorectal cancer stem cells and research progress of reverse transformation: a mini-review. Front Med (Lausanne). 2022;9: 995882.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"4073_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-020-00430-1","volume":"6","author":"HM Zhou","year":"2021","unstructured":"Zhou HM, et al. Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct Target Ther. 2021;6(1):62.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"4073_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s12032-021-01488-9","volume":"38","author":"X Lei","year":"2021","unstructured":"Lei X, et al. Cancer stem cells in colorectal cancer and the association with chemotherapy resistance. Med Oncol. 2021;38(4):43.","journal-title":"Med Oncol"},{"key":"4073_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061392","author":"PK Das","year":"2020","unstructured":"Das PK, Islam F, Lam AK. The roles of cancer stem cells and therapy resistance in colorectal carcinoma. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9061392.","journal-title":"Cells"},{"issue":"5","key":"4073_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000327815","volume":"34","author":"SR Bohl","year":"2011","unstructured":"Bohl SR, Pircher A, Hilbe W. Cancer stem cells: characteristics and their potential role for new therapeutic strategies. Onkologie. 2011;34(5):269\u201374.","journal-title":"Onkologie"},{"issue":"5","key":"4073_CR10","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3390\/cancers13051092","volume":"13","author":"C Hervieu","year":"2021","unstructured":"Hervieu C, et al. The role of cancer stem cells in colorectal cancer: from the basics to novel clinical trials. Cancers (Basel). 2021;13(5):1092.","journal-title":"Cancers (Basel)"},{"key":"4073_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.biocel.2019.02.010","volume":"110","author":"SM Parizadeh","year":"2019","unstructured":"Parizadeh SM, et al. Targeting cancer stem cells as therapeutic approach in the treatment of colorectal cancer. Int J Biochem Cell Biol. 2019;110:75\u201383.","journal-title":"Int J Biochem Cell Biol"},{"issue":"24","key":"4073_CR12","doi-asserted-by":"publisher","first-page":"10158","DOI":"10.1073\/pnas.0703478104","volume":"104","author":"P Dalerba","year":"2007","unstructured":"Dalerba P, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007;104(24):10158\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"70","key":"4073_CR13","doi-asserted-by":"publisher","first-page":"33403","DOI":"10.18632\/oncotarget.23607","volume":"9","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, et al. Cancer stem cells in progression of colorectal cancer. Oncotarget. 2018;9(70):33403\u201315.","journal-title":"Oncotarget"},{"issue":"2","key":"4073_CR14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40487-022-00205-4","volume":"10","author":"H Ehteram","year":"2022","unstructured":"Ehteram H, et al. Expression and prognostic significance of stem cell marker CD133 in survival rate of patients with colon cancer. Oncol Ther. 2022;10(2):451\u201361.","journal-title":"Oncol Ther"},{"issue":"2","key":"4073_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3892\/ol.2013.1723","volume":"7","author":"F Zhou","year":"2014","unstructured":"Zhou F, et al. Expression and prognostic value of tumor stem cell markers ALDH1 and CD133 in colorectal carcinoma. Oncol Lett. 2014;7(2):507\u201312.","journal-title":"Oncol Lett"},{"issue":"8","key":"4073_CR16","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1080\/07357900902744502","volume":"27","author":"D Horst","year":"2009","unstructured":"Horst D, et al. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 2009;27(8):844\u201350.","journal-title":"Cancer Invest"},{"key":"4073_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3389\/fonc.2019.00309","volume":"9","author":"Z Wang","year":"2019","unstructured":"Wang Z, et al. The prognostic and clinical value of CD44 in colorectal cancer: a meta-analysis. Front Oncol. 2019;9:309.","journal-title":"Front Oncol"},{"issue":"32","key":"4073_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016709","volume":"98","author":"YY Park","year":"2019","unstructured":"Park YY, et al. Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma. Medicine (Baltimore). 2019;98(32): e16709.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"4073_CR19","doi-asserted-by":"publisher","first-page":"1788366","DOI":"10.1080\/23723556.2020.1788366","volume":"7","author":"R Roudi","year":"2020","unstructured":"Roudi R, et al. Expression patterns and clinical significance of the potential cancer stem cell markers OCT4 and NANOG in colorectal cancer patients. Mol Cell Oncol. 2020;7(5):1788366.","journal-title":"Mol Cell Oncol"},{"issue":"3","key":"4073_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s10147-016-0959-z","volume":"21","author":"J Hamanishi","year":"2016","unstructured":"Hamanishi J, et al. PD-1\/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol. 2016;21(3):462\u201373.","journal-title":"Int J Clin Oncol"},{"key":"4073_CR21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","volume":"17","author":"X Wu","year":"2019","unstructured":"Wu X, et al. Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J. 2019;17:661\u201374.","journal-title":"Comput Struct Biotechnol J"},{"key":"4073_CR22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.biopha.2018.11.105","volume":"110","author":"N Yaghoubi","year":"2019","unstructured":"Yaghoubi N, et al. PD-1\/PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 2019;110:312\u20138.","journal-title":"Biomed Pharmacother"},{"key":"4073_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.21037\/tgh.2020.03.08","volume":"6","author":"R Breakstone","year":"2021","unstructured":"Breakstone R. Colon cancer and immunotherapy\u2014can we go beyond microsatellite instability? Transl Gastroenterol Hepatol. 2021;6:12.","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"1","key":"4073_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/jjco\/hyaa200","volume":"51","author":"H Hirano","year":"2021","unstructured":"Hirano H, et al. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer. Jpn J Clin Oncol. 2021;51(1):10\u20139.","journal-title":"Jpn J Clin Oncol"},{"issue":"26","key":"4073_CR25","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"key":"4073_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1034\/j.1600-065X.2002.18803.x","volume":"188","author":"MJ Scanlan","year":"2002","unstructured":"Scanlan MJ, et al. Cancer\/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002;188:22\u201332.","journal-title":"Immunol Rev"},{"key":"4073_CR27","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","volume":"9","author":"R Thomas","year":"2018","unstructured":"Thomas R, et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol. 2018;9:947.","journal-title":"Front Immunol"},{"issue":"4","key":"4073_CR28","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3892\/etm.2014.1913","volume":"8","author":"YY Long","year":"2014","unstructured":"Long YY, et al. Measurement of serum antibodies against NY-ESO-1 by ELISA: A guide for the treatment of specific immunotherapy for patients with advanced colorectal cancer. Exp Ther Med. 2014;8(4):1279\u201384.","journal-title":"Exp Ther Med"},{"issue":"5","key":"4073_CR29","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1158\/1078-0432.CCR-04-1365","volume":"11","author":"M Li","year":"2005","unstructured":"Li M, et al. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res. 2005;11(5):1809\u201314.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4073_CR30","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3390\/ph3072022","volume":"3","author":"PM Howell","year":"2010","unstructured":"Howell PM, Liu Z, Khong HT. Demethylating agents in the treatment of cancer. Pharmaceuticals. 2010;3(7):2022\u201344.","journal-title":"Pharmaceuticals"},{"issue":"5","key":"4073_CR31","first-page":"807","volume":"3","author":"HI Saba","year":"2007","unstructured":"Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag. 2007;3(5):807\u201317.","journal-title":"Ther Clin Risk Manag"},{"issue":"3 Suppl 2","key":"4073_CR32","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1053\/j.seminhematol.2005.05.009","volume":"42","author":"HI Saba","year":"2005","unstructured":"Saba HI, Wijermans PW. Decitabine in myelodysplastic syndromes. Semin Hematol. 2005;42(3 Suppl 2):S23-31.","journal-title":"Semin Hematol"},{"issue":"21","key":"4073_CR33","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4073_CR34","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1634\/theoncologist.2015-0298","volume":"21","author":"M Nieto","year":"2016","unstructured":"Nieto M, et al. The European Medicines Agency Review of Decitabine (Dacogen) for the treatment of adult patients with acute myeloid leukemia: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2016;21(6):692.","journal-title":"Oncologist"},{"issue":"9","key":"4073_CR35","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1080\/10428190701493910","volume":"48","author":"JE Kihslinger","year":"2007","unstructured":"Kihslinger JE, Godley LA. The use of hypomethylating agents in the treatment of hematologic malignancies. Leuk Lymphoma. 2007;48(9):1676\u201395.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"4073_CR36","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794\u2013803.","journal-title":"Cancer"},{"issue":"1","key":"4073_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-021-01154-x","volume":"13","author":"C Hu","year":"2021","unstructured":"Hu C, et al. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clin Epigenetics. 2021;13(1):1\u201316.","journal-title":"Clin Epigenetics"},{"issue":"2","key":"4073_CR38","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3892\/ol.2015.3253","volume":"10","author":"M Hosokawa","year":"2015","unstructured":"Hosokawa M, et al. Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine. Oncol Lett. 2015;10(2):761\u20137.","journal-title":"Oncol Lett"},{"key":"4073_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.895103","volume":"12","author":"G Yu","year":"2022","unstructured":"Yu G, et al. Synergistic therapeutic effects of low dose decitabine and NY-ESO-1 specific TCR-T cells for the colorectal cancer with microsatellite stability. Front Oncol. 2022;12: 895103.","journal-title":"Front Oncol"},{"issue":"1","key":"4073_CR40","doi-asserted-by":"publisher","first-page":"523","DOI":"10.4049\/jimmunol.1301342","volume":"192","author":"A Volont\u00e9","year":"2014","unstructured":"Volont\u00e9 A, et al. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J Immunol. 2014;192(1):523\u201332.","journal-title":"J Immunol"},{"issue":"20","key":"4073_CR41","first-page":"6735","volume":"63","author":"C Maccalli","year":"2003","unstructured":"Maccalli C, et al. Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. Cancer Res. 2003;63(20):6735\u201343.","journal-title":"Cancer Res"},{"issue":"3","key":"4073_CR42","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1136\/gutjnl-2015-309453","volume":"66","author":"D Mennonna","year":"2017","unstructured":"Mennonna D, et al. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes. Gut. 2017;66(3):454\u201363.","journal-title":"Gut"},{"key":"4073_CR43","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3389\/fonc.2018.00399","volume":"8","author":"AQ Khan","year":"2018","unstructured":"Khan AQ, et al. Curcumin-mediated degradation of S-phase kinase protein 2 induces cytotoxic effects in human papillomavirus-positive and negative squamous carcinoma cells. Front Oncol. 2018;8:399.","journal-title":"Front Oncol"},{"issue":"5","key":"4073_CR44","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.3892\/ol.2014.2499","volume":"8","author":"B Wang","year":"2014","unstructured":"Wang B, et al. Decitabine inhibits the cell growth of cholangiocarcinoma in cultured cell lines and mouse xenografts. Oncol Lett. 2014;8(5):1919\u201324.","journal-title":"Oncol Lett"},{"issue":"3","key":"4073_CR45","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/jmv.24634","volume":"89","author":"M Nakamura","year":"2017","unstructured":"Nakamura M, et al. Decitabine inhibits tumor cell proliferation and up-regulates e-cadherin expression in Epstein-Barr virus-associated gastric cancer. J Med Virol. 2017;89(3):508\u201317.","journal-title":"J Med Virol"},{"issue":"4","key":"4073_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060516","volume":"8","author":"H-X Lin","year":"2013","unstructured":"Lin H-X, et al. Decreased expression of Beclin 1 correlates closely with Bcl-xL expression and poor prognosis of ovarian carcinoma. PLoS ONE. 2013;8(4): e60516.","journal-title":"PLoS ONE"},{"issue":"4","key":"4073_CR47","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.7314\/APJCP.2012.13.4.1639","volume":"13","author":"L-W Xu","year":"2012","unstructured":"Xu L-W, et al. Expression and significance of microsomal prostaglandin synthase-1 (mPGES-1) and Beclin-1 in the development of prostate cancer. Asian Pac J Cancer Prev. 2012;13(4):1639\u201344.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"18","key":"4073_CR48","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1038\/onc.2012.252","volume":"32","author":"C Gong","year":"2013","unstructured":"Gong C, et al. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like\/progenitor cells. Oncogene. 2013;32(18):2261\u201372.","journal-title":"Oncogene"},{"issue":"12","key":"4073_CR49","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/j.1600-0463.2007.00858.x","volume":"115","author":"CH Ahn","year":"2007","unstructured":"Ahn CH, et al. Expression of beclin-1, an autophagy-related protein, in gastric and colorectal cancers. APMIS. 2007;115(12):1344\u20139.","journal-title":"APMIS"},{"issue":"1","key":"4073_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2867-13-26","volume":"13","author":"X Li","year":"2013","unstructured":"Li X, et al. Beclin1 inhibition promotes autophagy and decreases gemcitabine\u2013induced apoptosis in Miapaca2 pancreatic cancer cells. Cancer Cell Int. 2013;13(1):1\u20139.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"4073_CR51","first-page":"1866","volume":"43","author":"CL Wu","year":"2019","unstructured":"Wu CL, et al. Beclin1 inhibition enhances paclitaxel-mediated cytotoxicity in breast cancer in vitro and in vivo. Int J Mol Med. 2019;43(4):1866\u201378.","journal-title":"Int J Mol Med"},{"issue":"3","key":"4073_CR52","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.lungcan.2013.05.009","volume":"81","author":"JY Shin","year":"2013","unstructured":"Shin JY, et al. Overexpression of beclin1 induced autophagy and apoptosis in lungs of K-rasLA1 mice. Lung Cancer. 2013;81(3):362\u201370.","journal-title":"Lung Cancer"},{"issue":"4","key":"4073_CR53","first-page":"1927","volume":"40","author":"J Zhu","year":"2018","unstructured":"Zhu J, et al. Beclin1 overexpression suppresses tumor cell proliferation and survival via an autophagy-dependent pathway in human synovial sarcoma cells. Oncol Rep. 2018;40(4):1927\u201336.","journal-title":"Oncol Rep"},{"issue":"5","key":"4073_CR54","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1159\/000447882","volume":"39","author":"X Wu","year":"2016","unstructured":"Wu X, et al. Role of Beclin-1-mediated autophagy in the survival of pediatric leukemia cells. Cell Physiol Biochem. 2016;39(5):1827\u201336.","journal-title":"Cell Physiol Biochem"},{"issue":"21","key":"4073_CR55","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1182\/blood.V120.21.1833.1833","volume":"120","author":"K Maes","year":"2012","unstructured":"Maes K, et al. The DNA methyltransferase inhibitor decitabine induces DNA damage, cell cycle arrest and apoptosis in multiple myeloma. Blood. 2012;120(21):1833.","journal-title":"Blood"},{"issue":"6","key":"4073_CR56","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.urology.2007.11.029","volume":"71","author":"D Shang","year":"2008","unstructured":"Shang D, et al. Demethylating agent 5-aza-2\u2032-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin. Urology. 2008;71(6):1220\u20135.","journal-title":"Urology"},{"issue":"8","key":"4073_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162105","volume":"11","author":"C Riccadonna","year":"2016","unstructured":"Riccadonna C, et al. Decitabine treatment of glioma-initiating cells enhances immune recognition and killing. PLoS ONE. 2016;11(8): e0162105.","journal-title":"PLoS ONE"},{"issue":"2","key":"4073_CR58","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00280-011-1708-7","volume":"69","author":"Y Jia","year":"2012","unstructured":"Jia Y, et al. Inhibition of glutathione synthesis reverses Kr\u00fcppel-like factor 4-mediated cisplatin resistance. Cancer Chemother Pharmacol. 2012;69(2):377\u201385.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"4073_CR59","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrc2499","volume":"8","author":"JE Visvader","year":"2008","unstructured":"Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755\u201368.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"4073_CR60","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj M, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci. 2003;100(7):3983\u20138.","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"4073_CR61","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.3390\/ijms18122574","volume":"18","author":"M Prieto-Vila","year":"2017","unstructured":"Prieto-Vila M, et al. Drug resistance driven by cancer stem cells and their niche. Int J Mol Sci. 2017;18(12):2574.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4073_CR62","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.stem.2007.06.002","volume":"1","author":"PC Hermann","year":"2007","unstructured":"Hermann PC, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1(3):313\u201323.","journal-title":"Cell Stem Cell"},{"key":"4073_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biocel.2018.10.013","volume":"106","author":"GY Liou","year":"2019","unstructured":"Liou GY. CD133 as a regulator of cancer metastasis through the cancer stem cells. Int J Biochem Cell Biol. 2019;106:1\u20137.","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"4073_CR64","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","volume":"11","author":"C Chen","year":"2018","unstructured":"Chen C, et al. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11(1):64.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4073_CR65","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40164-020-00192-0","volume":"9","author":"H Xu","year":"2020","unstructured":"Xu H, et al. CD44 as a tumor biomarker and therapeutic target. Exp Hematol Oncol. 2020;9(1):36.","journal-title":"Exp Hematol Oncol"},{"issue":"17","key":"4073_CR66","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.3748\/wjg.v19.i17.2603","volume":"19","author":"F Ren","year":"2013","unstructured":"Ren F, Sheng W-Q, Du X. CD133: a cancer stem cells marker, is used in colorectal cancers. World J Gastroenterol: WJG. 2013;19(17):2603.","journal-title":"World J Gastroenterol: WJG"},{"issue":"3","key":"4073_CR67","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/modpathol.2009.181","volume":"23","author":"CW Ong","year":"2010","unstructured":"Ong CW, et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol. 2010;23(3):450\u20137.","journal-title":"Mod Pathol"},{"issue":"5","key":"4073_CR68","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1158\/0008-5472.CAN-08-2023","volume":"69","author":"NA Dallas","year":"2009","unstructured":"Dallas NA, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Can Res. 2009;69(5):1951\u20137.","journal-title":"Can Res"},{"issue":"1","key":"4073_CR69","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc1780","volume":"6","author":"BD Rowland","year":"2006","unstructured":"Rowland BD, Peeper DS. KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer. 2006;6(1):11\u201323.","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"4073_CR70","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1093\/nar\/28.15.2969","volume":"28","author":"J-L Shie","year":"2000","unstructured":"Shie J-L, et al. Gut-enriched Kr\u00fcppel-like factor represses cyclin D1 promoter activity through Sp1 motif. Nucleic Acids Res. 2000;28(15):2969\u201376.","journal-title":"Nucleic Acids Res"},{"issue":"37","key":"4073_CR71","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1038\/onc.2012.461","volume":"32","author":"J Zhang","year":"2013","unstructured":"Zhang J, et al. NANOG modulates stemness in human colorectal cancer. Oncogene. 2013;32(37):4397\u2013405.","journal-title":"Oncogene"},{"issue":"11","key":"4073_CR72","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1016\/j.celrep.2015.11.022","volume":"13","author":"N Li","year":"2015","unstructured":"Li N, et al. The Msi family of RNA-binding proteins function redundantly as intestinal oncoproteins. Cell Rep. 2015;13(11):2440\u201355.","journal-title":"Cell Rep"},{"issue":"2","key":"4073_CR73","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3892\/ijo.2014.2749","volume":"46","author":"C Gao","year":"2015","unstructured":"Gao C, et al. Downregulation of Msi1 suppresses the growth of human colon cancer by targeting p21cip1. Int J Oncol. 2015;46(2):732\u201340.","journal-title":"Int J Oncol"},{"issue":"8","key":"4073_CR74","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1023\/A:1024763723240","volume":"48","author":"S Nishimura","year":"2003","unstructured":"Nishimura S, et al. Expression of Musashi-1 in human normal colon crypt cells: a possible stem cell marker of human colon epithelium. Dig Dis Sci. 2003;48(8):1523\u20139.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"4073_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-02057-9","volume":"7","author":"G-Y Chiou","year":"2017","unstructured":"Chiou G-Y, et al. Musashi-1 promotes a cancer stem cell lineage and chemoresistance in colorectal cancer cells. Sci Rep. 2017;7(1):1\u201313.","journal-title":"Sci Rep"},{"issue":"1","key":"4073_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hemonc.2013.09.005","volume":"7","author":"S Afreen","year":"2014","unstructured":"Afreen S, Dermime S. The immunoinhibitory B7\u2013H1 molecule as a potential target in cancer: killing many birds with one stone. Hematol Oncol Stem Cell Ther. 2014;7(1):1\u201317.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"Suppl 1","key":"4073_CR77","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","volume":"24","author":"L Xia","year":"2019","unstructured":"Xia L, Liu Y, Wang Y. PD-1\/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist. 2019;24(Suppl 1):S31.","journal-title":"Oncologist"},{"key":"4073_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.10.004","author":"TC Zhou","year":"2017","unstructured":"Zhou TC, et al. A review of the PD-1\/PD-L1 checkpoint in bladder cancer: from mediator of immune escape to target for treatment. Urol Oncol. 2017. https:\/\/doi.org\/10.1016\/j.urolonc.2016.10.004.","journal-title":"Urol Oncol"},{"key":"4073_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.762341","volume":"12","author":"D Wang","year":"2021","unstructured":"Wang D, et al. Clinical application of adaptive immune therapy in MSS colorectal cancer patients. Front Immunol. 2021;12: 762341.","journal-title":"Front Immunol"},{"issue":"10","key":"4073_CR80","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1080\/14712598.2021.1933940","volume":"21","author":"C Wang","year":"2021","unstructured":"Wang C, Fakih M. Targeting MSS colorectal cancer with immunotherapy: are we turning the corner? Expert Opin Biol Ther. 2021;21(10):1347\u201357.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"4073_CR81","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott PA, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318\u201327.","journal-title":"J Clin Oncol"},{"issue":"34","key":"4073_CR82","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","volume":"34","author":"AI Daud","year":"2016","unstructured":"Daud AI, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 2016;34(34):4102\u20139.","journal-title":"J Clin Oncol"},{"key":"4073_CR83","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018. https:\/\/doi.org\/10.1126\/science.aar3593.","journal-title":"Science"},{"key":"4073_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.685370","volume":"12","author":"R Liu","year":"2021","unstructured":"Liu R, et al. Influence of tumor immune infiltration on immune checkpoint inhibitor therapeutic efficacy: a computational retrospective study. Front Immunol. 2021;12: 685370.","journal-title":"Front Immunol"},{"issue":"1","key":"4073_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-33927-5","volume":"8","author":"C-Y Huang","year":"2018","unstructured":"Huang C-Y, et al. Clinical significance of programmed death 1 ligand-1 (CD274\/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II\u2013III colorectal cancer. Sci Rep. 2018;8(1):1\u201310.","journal-title":"Sci Rep"},{"issue":"2","key":"4073_CR86","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3390\/cancers12020462","volume":"12","author":"KC-Y Huang","year":"2020","unstructured":"Huang KC-Y, et al. Decitabine augments chemotherapy-induced PD-L1 upregulation for PD-L1 blockade in colorectal cancer. Cancers. 2020;12(2):462.","journal-title":"Cancers"},{"issue":"9","key":"4073_CR87","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","volume":"5","author":"A Ribas","year":"2015","unstructured":"Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5(9):915\u20139.","journal-title":"Cancer Discov"},{"issue":"6","key":"4073_CR88","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1433981","volume":"7","author":"M Dosset","year":"2018","unstructured":"Dosset M, et al. PD-1\/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncoimmunology. 2018;7(6): e1433981.","journal-title":"Oncoimmunology"},{"issue":"1","key":"4073_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-020-02306-y","volume":"18","author":"A Raza","year":"2020","unstructured":"Raza A, et al. Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy. J Transl Med. 2020;18(1):1\u201311.","journal-title":"J Transl Med"},{"issue":"8","key":"4073_CR90","first-page":"2690","volume":"8","author":"S Coral","year":"2002","unstructured":"Coral S, et al. 5-aza-2\u2032-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res. 2002;8(8):2690\u20135.","journal-title":"Clin Cancer Res"},{"key":"4073_CR91","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3389\/fimmu.2018.01769","volume":"9","author":"M Merhi","year":"2018","unstructured":"Merhi M, et al. Squamous cell carcinomas of the head and neck cancer response to programmed cell death protein-1 targeting and differential expression of immunological markers: a case report. Front Immunol. 2018;9:1769.","journal-title":"Front Immunol"},{"key":"4073_CR92","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001278","author":"M Merhi","year":"2020","unstructured":"Merhi M, et al. Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-001278.","journal-title":"J Immunother Cancer"},{"key":"4073_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.781872","volume":"12","author":"S Dermime","year":"2021","unstructured":"Dermime S, Merhi M, Merghoub T. Editorial: dynamic biomarkers of response to anti-immune checkpoint inhibitors in cancer. Front Immunol. 2021;12: 781872.","journal-title":"Front Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04073-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04073-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04073-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T16:05:42Z","timestamp":1680278742000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04073-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4073"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04073-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]},"assertion":[{"value":"22 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board committee of Hamad Medical Corporation, Doha, Qatar.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the manuscript for submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"235"}}